EP1070122A4 - INDUCTION OF THE EXPRESSION OF APOPTOTIC OR CYTOTOXIC GENES BY CO-SUPPORT OF ADENOVIRAL MEDIATED GENES - Google Patents

INDUCTION OF THE EXPRESSION OF APOPTOTIC OR CYTOTOXIC GENES BY CO-SUPPORT OF ADENOVIRAL MEDIATED GENES

Info

Publication number
EP1070122A4
EP1070122A4 EP99913854A EP99913854A EP1070122A4 EP 1070122 A4 EP1070122 A4 EP 1070122A4 EP 99913854 A EP99913854 A EP 99913854A EP 99913854 A EP99913854 A EP 99913854A EP 1070122 A4 EP1070122 A4 EP 1070122A4
Authority
EP
European Patent Office
Prior art keywords
genes
expression
apoptotic
induction
support
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99913854A
Other languages
German (de)
French (fr)
Other versions
EP1070122A2 (en
Inventor
Timothy J Mcdonnell
Stephen G Swisher
Bingliang Fang
Elizabeth M Bruckheimer
Mona G Sarkiss
Li Ji
Jack A Roth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of EP1070122A2 publication Critical patent/EP1070122A2/en
Publication of EP1070122A4 publication Critical patent/EP1070122A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention generally relates to viral vectors and their use as expression vectors for transforming human cells, both in vitro and in vivo. More particularly, the present invention relates to adenoviral vectors containing propapoptotic genes and their use in cancer therapy.
EP99913854A 1998-03-11 1999-03-11 INDUCTION OF THE EXPRESSION OF APOPTOTIC OR CYTOTOXIC GENES BY CO-SUPPORT OF ADENOVIRAL MEDIATED GENES Withdrawn EP1070122A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7754198P 1998-03-11 1998-03-11
US77541P 1998-03-11
PCT/US1999/005359 WO1999046371A2 (en) 1998-03-11 1999-03-11 Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery

Publications (2)

Publication Number Publication Date
EP1070122A2 EP1070122A2 (en) 2001-01-24
EP1070122A4 true EP1070122A4 (en) 2004-11-10

Family

ID=22138678

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99913854A Withdrawn EP1070122A4 (en) 1998-03-11 1999-03-11 INDUCTION OF THE EXPRESSION OF APOPTOTIC OR CYTOTOXIC GENES BY CO-SUPPORT OF ADENOVIRAL MEDIATED GENES

Country Status (4)

Country Link
EP (1) EP1070122A4 (en)
AU (1) AU762493B2 (en)
CA (1) CA2322663A1 (en)
WO (1) WO1999046371A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001073093A2 (en) * 2000-03-24 2001-10-04 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
EP1287153B1 (en) 2000-05-31 2009-09-30 Human Gene Therapy Research Institute Methods and compositions for efficient gene transfer using transcomplementary vectors
WO2001093899A1 (en) * 2000-06-02 2001-12-13 Hiroshi Okamoto PANCREATIC LANGERHANS β CELL PROLIFERATION PROMOTER AND APOPTOSIS INHIBITOR, AND SCREENING OF CANDIDATE COMPOUNDS FOR THE E DRUGS
US6579522B1 (en) 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
EP1207205A1 (en) * 2000-11-20 2002-05-22 Crucell Holland B.V. Adenoviral replicons
US20030086903A1 (en) 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
WO2003057158A2 (en) 2001-12-31 2003-07-17 Dana-Farber Cancer Institute, Inc. Method of treating apoptosis and compositions thereof
JP4511108B2 (en) 2002-05-31 2010-07-28 オンコリクス インコーポレイテッド Human prolactin antagonist-angiogenesis inhibitor fusion protein
CN100361710C (en) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 Construction and application of oncolytic adenovirus recombinant of tumor cell specifically expressing immunoregulation factor GM-CSF
US20080081354A1 (en) * 2006-10-02 2008-04-03 Cardiac Pacemakers, Inc. Devices, vectors and methods for inducible ischemia cardioprotection
EP3541803B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
MA50509A (en) 2017-11-03 2021-06-02 Amgen Inc APJ RECEPTOR FUSED TRIAZOLE AGONISTS
US11807624B2 (en) 2018-05-01 2023-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the APJ receptor
CN110174456B (en) * 2019-06-11 2021-09-21 华润双鹤药业股份有限公司 Method for measuring lung surfactant protein and application thereof
CN117731804A (en) * 2023-11-10 2024-03-22 南开大学 Multi-gene nano-carrier, preparation method and application thereof, and anticancer drug

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996025507A2 (en) * 1995-02-17 1996-08-22 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of preparation and use of recombinant adenoviral vectors
WO1997040180A1 (en) * 1996-04-20 1997-10-30 Boehringer Ingelheim International Gmbh Chicken embryo lethal orphan (celo) virus
WO2000015648A1 (en) * 1998-09-10 2000-03-23 The Uab Research Foundation Adenoviral vector encoding pro-apoptotic bax gene and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996025507A2 (en) * 1995-02-17 1996-08-22 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of preparation and use of recombinant adenoviral vectors
WO1997040180A1 (en) * 1996-04-20 1997-10-30 Boehringer Ingelheim International Gmbh Chicken embryo lethal orphan (celo) virus
WO2000015648A1 (en) * 1998-09-10 2000-03-23 The Uab Research Foundation Adenoviral vector encoding pro-apoptotic bax gene and uses thereof

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
"RETROVIRAL BAX GENE TRANSFER FAILS TO SENSITIZE MALIGNANT GLIOMA CELLS TO CD95L-INDUCED APOPTOSIS AND CANCER CHEMOTHERAPY", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 77, August 1998 (1998-08-01), pages 645 - 648, XP002922344, ISSN: 0020-7136 *
BOISE L H ET AL: "BCL-X, A BCL-2-RELATED GENE THAT FUNCTIONS AS A DOMINANT REGULATOR OF APOPTOTIC CELL DEATH", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 74, 27 August 1993 (1993-08-27), pages 597 - 608, XP002018919, ISSN: 0092-8674 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1996, SIMONIAN PHILIP L ET AL: "Bax homodimerization is not required for bax to accelerate chemotherapy-induced cell death", XP002282530, Database accession no. PREV199799338036 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1996, ZHA HONGBIN ET AL: "Proapoptotic protein bax heterodimerizes with Bcl-2 and homodimerizes with bax via a novel domain (BH3) distinct from BH1 and BH2", XP002282529, Database accession no. PREV199698772776 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; December 1993 (1993-12-01), KORSMEYER S J ET AL: "Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death.", XP002282531, Database accession no. NLM8142617 *
DERROW S ET AL: "Apoptosis induction by adenovirus-bclx-s: A rational strategy for bladder cancer gene therapy", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 38, no. 0, 1997, & EIGHTY-EIGHTH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; SAN DIEGO, CALIFORNIA, USA; APRIL 12-16, 1997, pages 11, XP002282532, ISSN: 0197-016X *
DERROW SOL ET AL: "Apoptosis induction by adenovirus-BCLX-S: A rational strategy for bladder cancer gene therapy", JOURNAL OF UROLOGY, vol. 157, no. 4 SUPPL., 1997, & 92ND ANNUAL MEETING OF THE AMERICAN UROLOGICAL ASSOCIATION; NEW ORLEANS, LOUISIANA, USA; APRIL 12-17, 1997, pages 310, XP008031086, ISSN: 0022-5347 *
JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 13, 1996, pages 7440 - 7444, ISSN: 0021-9258 *
JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 50, 1996, pages 32073 - 32077, ISSN: 0021-9258 *
KAGAWA S ET AL: "Induction of bax gene expression by adenoviral mediated gene codelivery", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 40, March 1999 (1999-03-01), & 90TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; PHILADELPHIA, PENNSYLVANIA, USA; APRIL 10-14, 1999, pages 218, XP002282528, ISSN: 0197-016X *
See also references of WO9946371A3 *
SEMINARS IN CANCER BIOLOGY. DEC 1993, vol. 4, no. 6, December 1993 (1993-12-01), pages 327 - 332, ISSN: 1044-579X *

Also Published As

Publication number Publication date
WO1999046371A9 (en) 2000-02-17
AU762493B2 (en) 2003-06-26
WO1999046371A3 (en) 2000-08-24
WO1999046371A2 (en) 1999-09-16
CA2322663A1 (en) 1999-09-16
EP1070122A2 (en) 2001-01-24
AU3183799A (en) 1999-09-27

Similar Documents

Publication Publication Date Title
EP1070122A4 (en) INDUCTION OF THE EXPRESSION OF APOPTOTIC OR CYTOTOXIC GENES BY CO-SUPPORT OF ADENOVIRAL MEDIATED GENES
FI963103A0 (en) Non-viral vector
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
EP1017797A4 (en) NON-ORIGINATING PRIMATE LENTIVIRUS VECTORS AND PACKAGING SYSTEMS
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
TWI256891B (en) 17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations
HUP9902310A2 (en) Complementary adenoviral vector systems and cell lines
BR9910251A (en) Hematopoietic stimulation
PL339735A1 (en) Pappiloma virus capsomer vaccine compositions and methods of applying them
HK1038744A1 (en) Compounds useful in the treatment of inflammatory diseases
AU1543895A (en) Chloropyrimidine intermediates
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
EP0769968A4 (en) RETROVIRAL VECTORS PRODUCED BY HUMAN SERUM LYSE RESISTANT PRODUCT CELL LINES
AUPO811797A0 (en) Tropoelastin derivatives
CA2130360A1 (en) Sulfonic Acid Derivatives in the Treatment of Viral Diseases
BR0009211A (en) Resorcinol derivatives
AU3209300A (en) Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines
AU4985596A (en) Novel aroylaniline derivatives, compositions and uses thereof in the treatment of viral infections
CA2271478A1 (en) Tissue specific expression of retinoblastoma protein
WO2000006735A8 (en) Interferon alpha hybrids
AU3880900A (en) Surface localized colligin/hsp47 in carcinoma cells
AU2002246455A1 (en) Fusion proteins for specific treatment of cancer and auto-immune diseases
CA2385872A1 (en) Gene transfer in human lymphocytes using retroviral scfv cell targeting
MXPA02003731A (en) Novel fusidic acid derivatives.
TR200003352T2 (en) New pentaerythrit derivatives, their manufacture and uses, and intermediates for their synthesis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001011

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 35/00 B

Ipc: 7A 61K 48/00 B

Ipc: 7C 12N 15/86 B

Ipc: 7A 01N 43/04 B

Ipc: 7C 12N 15/00 A

A4 Supplementary search report drawn up and despatched

Effective date: 20040922

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ROTH, JACK, A.

Inventor name: JI, LI

Inventor name: SARKISS, MONA, G.

Inventor name: BRUCKHEIMER, ELIZABETH, M.

Inventor name: FANG, BINGLIANG

Inventor name: SWISHER, STEPHEN, G.

Inventor name: MCDONNELL, TIMOTHY, J.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ROTH, JACK, A.

Inventor name: JI, LI

Inventor name: SARKISS, MONA, G.

Inventor name: BRUCKHEIMER, ELIZABETH, M.

Inventor name: FANG, BINGLIANG

Inventor name: SWISHER, STEPHEN, G.

Inventor name: MCDONNELL, TIMOTHY, J.

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20070515BHEP

Ipc: A61K 48/00 20060101ALI20070515BHEP

Ipc: C12N 15/861 20060101ALI20070515BHEP

Ipc: C12N 15/86 20060101ALI20070515BHEP

Ipc: A01N 43/04 20060101ALI20070515BHEP

Ipc: C12N 15/00 20060101AFI20070515BHEP

RTI1 Title (correction)

Free format text: ADENOVIRUS FOR THE INDUCTION OF APOPTIC GENE EXPRESSION

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ROTH, JACK, A.

Inventor name: JI, LI

Inventor name: SARKISS, MONA, G.

Inventor name: BRUCKHEIMER, ELIZABETH, M.

Inventor name: FANG, BINGLIANG

Inventor name: SWISHER, STEPHEN, G.

Inventor name: MCDONNELL, TIMOTHY, J.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20081001